CA3224341A1 — Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers
Assigned to Novartis AG · Expires 2023-03-09 · 3y expired
What this patent protects
The invention relates to a pharmaceutical combination comprising a TEAD inhibitor in combination with a first and optionally a second therapeutically active agent. The present invention also relates to methods of treating cancer involving administering to a subject in need thereo…
USPTO Abstract
The invention relates to a pharmaceutical combination comprising a TEAD inhibitor in combination with a first and optionally a second therapeutically active agent. The present invention also relates to methods of treating cancer involving administering to a subject in need thereof the TEAD inhibitor in combination with the first and optionally the second therapeutically active agent.
Drugs covered by this patent
- Lumakras (SOTORASIB) · Amgen
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.